Company News

Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year.

Orthocell has recorded a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter.

Orthocell has announced the submission of its U.S. FDA 510(k) regulatory application for clearance to commercially distribute Remplir™ into the…

Orthocell has today announced the achievement of first sales of Remplir™ in Singapore, marking another significant milestone in its global…

Orthocell has today reached another significant milestone with the successful completion of its Remplir™ 510(k) nerve repair regulatory study, validating…

Orthocell has announced that it has appointed Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair…

Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US…

Orthocell has today announced that it has received firm commitments for a $17 million capital raising via an institutional placement.

Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of…

Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+™ and Remplir™.